<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01831531</url>
  </required_header>
  <id_info>
    <org_study_id>ESO-Shanghai7</org_study_id>
    <nct_id>NCT01831531</nct_id>
  </id_info>
  <brief_title>Study of S-1 in Combination With Radiotherapy in Esophageal Cancer</brief_title>
  <official_title>Phase II Study of S-1 in Combination With Radiotherapy in Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to study the safety, the local control, and the overall survival of S-1
      combined with radiotherapy for patients with esophageal squamous cell carcinoma. 105 patients
      will be recruited into this trial.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>1 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>3-yr local control rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive chemoradiation with S-1.
Interventions:
Drug: S-1 Radiation: Radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA &gt;1.6 m2) p.o bid d1-28</description>
    <arm_group_label>S-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.</description>
    <arm_group_label>S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Joined the study voluntarily and signed informed consent form;

          -  Age ＞75 or age 18-75 who are intolerant of or reject intravenous chemotherapy

          -  Both genders

          -  Esophageal squamous cell carcinoma confirmed by pathology

          -  Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a,TxN1M0-1a,TxNxM1a,
             AJCC 6th)

          -  No radiotherapy, chemotherapy or other treatments prior to enrollment

          -  PS ECOG 0-2

          -  Life expectancy of more than 3 months

          -  Hemoglobin（Hb）≥9 g/dL

          -  WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L

          -  platelet count (Pt) ≥100x 109/L

          -  Hepatic function: ALAT and ASAT &lt; 2.5 x ULN, TBIL&lt;1.5 x ULN

          -  Renal function: creatinine &lt; 1.5 x ULN

          -  No immuno-deficiency

          -  Use of an effective contraceptive for adults to prevent pregnancy.

        Exclusion Criteria:

          -  Complete esophageal obstruction

          -  Deep esophageal ulcer

          -  Esophageal perforation

          -  Haematemesis

          -  After surgery, exploratory thoracotomy, radiotherapy, chemotherapy, or targeting
             therapy

          -  Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in
             situ, who survived with no evidence disease for over 3 years

          -  Participation in other interventional clinical trials within 30 days

          -  Pregnant or breast-feeding women or people during the birth-period who refused to take
             contraceptives

          -  Drug addiction

          -  Alcoholism or AIDS

          -  Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior

          -  Patient who has metastasis such as lung, liver metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuaile Zhao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2013</study_first_submitted>
  <study_first_submitted_qc>April 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Kuai Le Zhao, MD</investigator_full_name>
    <investigator_title>Professor of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

